Research Article

The Effect of Cordycepin on Steroidogenesis and Apoptosis in MA-10 Mouse Leydig Tumor Cells

Bo-Syong Pan, Chun-Yu Lin, and Bu-Miin Huang

Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan

Correspondence should be addressed to Bu-Miin Huang, bumiin@mail.ncku.edu.tw

Received 9 November 2010; Revised 25 January 2011; Accepted 30 March 2011

Cordycepin is a natural pure compound extracted from Cordyceps sinensis (CS). We have demonstrated that CS stimulates steroidogenesis in primary mouse Leydig cell and activates apoptosis in MA-10 mouse Leydig tumor cells. It is highly possible that cordycepin is the main component in CS modulating Leydig cell functions. Thus, our aim was to investigate the steroidogenic and apoptotic effects with potential mechanism of cordycepin on MA-10 mouse Leydig tumor cells. Results showed that cordycepin significantly stimulated progesterone production in dose- and time-dependent manners. Adenosine receptor (AR) subtype agonists were further used to treat MA-10 cells, showing that A1, A2A, A2B, and A3, AR agonists could stimulate progesterone production. However, StAR promoter activity and protein expression remained of no difference among all cordycepin treatments, suggesting that cordycepin might activate AR, but not stimulated StAR protein to regulate MA-10 cell steroidogenesis. Meanwhile, cordycepin could also induce apoptotic cell death in MA-10 cells. Moreover, four AR subtype agonists induced cell death in a dose-dependent manner, and four AR subtype antagonists could all rescue cell death under cordycepin treatment in MA-10 cells. In conclusion, cordycepin could activate adenosine subtype receptors and simultaneously induce steroidogenesis and apoptosis in MA-10 mouse Leydig tumor cells.

1. Introduction

Cordyceps sinensis (CS) is an ingredient of traditional Chinese medicine and is prescribed for replenish the kidney and soothe the lung and for the treatment of fatigue [1]. Cordycepin (3'-deoxyadenosine, an adenosine analogue) is a pure component extracted from the mycelia of CS, and it is well known to possess anticancer ability which induce apoptosis in HeLa cells, oral cancer cells, breast cancer cells, leukemia, and lymphoma cell lines [2–5]. Previous studies demonstrated that CS alone could stimulate steroid production in both normal and tumor mouse Leydig cells [6, 7] and activate apoptosis in MA-10 mouse Leydig tumor cells [8]. It is highly possible that cordycepin is the main component in CS modulating Leydig cell functions. Thus, the aim of the present study was to investigate the steroidogenic and apoptotic effects with potential mechanism of cordycepin on MA-10 mouse Leydig tumor cells.

Steroidogenesis, steroid hormone biosynthesis, occurs mainly in the adrenal glands, brain, placenta, testes, and ovaries [9]. In the male reproduction system, steroidogenesis in Leydig cells is regulated by luteinizing hormone (LH)/human chorionic gonadotropin (hCG). LH and hCG activate its cognate receptors and coupling to the adenylate cyclase (AC) through the heterotrimeric guanine nucleotide-binding regulatory protein (G-protein) [10, 11]. The activated GTP-bound subunit of G-protein would be able to activate adenylyl cyclase, which results in the hydrolysis of ATP to cyclic AMP. Once cAMP is synthesized, the following activation of protein kinase A (PKA) pathway would phosphorylate steroidogenic acute regulatory protein (StAR) [12]. The StAR protein, a 30 kDa phosphoprotein, is the rate-limiting step which delivers cholesterol from the outer to the inner mitochondrial membrane [13]. After translocation into mitochondrial, P450 side chain cleave enzyme (P450scc) converts cholesterol to pregnenolone [14]. When pregnenolone is formed, it may be metabolized to progesterone by mitochondrial 3β-hydroxysteroid dehydrogenase (3β-HSD), or it may exit the mitochondria and undergo further metabolism with the final steroid hormone product dependent upon the nature of the tissue [15, 16]. It has been well demonstrated that adenosine acts through four G-protein-coupled membrane receptors, the A1, A2A, A2B, and A3 adenosine receptors [17]. The adenosine
A₁ and A₃ receptors (A₁-AR and A₃-AR) inhibit adenylate cyclase via Gₛ and activate phospholipase C (PLC) [18, 19], and the adenosine A₂A and A₂B receptors (A₂A-AR and A₂B-AR) stimulate adenyl cyclase via Gₛ [20, 21], respectively. It is also shown that adenosine appears to induce cell death through apoptosis, whereas ATP appears to cause both necrosis and apoptosis [22].

Although some reports have showed that cordycepin possesses anticancer ability, there is still no research about cordycepin on gonadal steroidogenesis. In fact, we have demonstrated that cordycepin could stimulate testosterone production in normal mouse primary Leydig cells without any phenomenon of cell death [23]. Since the isolation of primary Leydig cell is complicated with very low yield from mouse testis, MA-10 mouse Leydig tumor cell line was then used to further examine the regulatory mechanisms regarding the effects of cordycepin. Interestingly, we did find that cordycepin could induce MA-10 cell steroidogenesis and apoptosis. Thus, our objective was to investigate the effect of cordycepin on Leydig cell steroidogenesis and apoptosis with the preliminarily possible mechanisms.

2. Materials and Methods

2.1. Chemicals. Cordycepin, bovine serum albumin (BSA), Waymouth MB 752/1 medium, N₆-cyclopentyladenosine (CPA), 2-p-(2-carboxyethyl) phenethylamino-5′-N-ethyl-carboxamidoadenosine (CGS-21680), 5′-N-ethylcarboxamidoadenosine (NECA), N₆-(3-iodobenzyl) adenosine-5′-N-methyluronamide (IB-MECA), 8-Cyclopentyl-1,3-di-propylxanthine (DPCPX), 8-(3-Chlorostyryl) caffeine (CSC), 8-[4-([(4-Cyanophenyl)carbamoylmethyl]oxy)phenyl]-1,3-di(n-propyl) xanthine (MRS 1754), 3-Ethyl-5-benzyl-2-methyl-4-phenylethylthethyl-6-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (MRS 1191), human choricon gonadotropin (hCG) (10,000 IU per gram) and methyl-thiiazolecotorazoli-um (MTT) were purchased from Sigma Chemical (St. Louis, mo, USA). Fetal bovine serum (FBS), Dulbecco's phosphate-buffered saline, lyophilized trypsin-EDTA, and gentamicin sulfate were purchased from Gibco (Grand Island, NY, USA). Sodium hydroxide, hydrochloric acid, Sodium dodecyl sulfate (SDS), sucrose, EDTA, isopropyl alcohol, chloroform, and Tween 20 were purchased from Merck (Darmstadt, Germany). Tris base was purchased from Calbiochem (San Deigo, Calif, USA). Acrylamide was purchased from J.T. Baker (Phillipsburg, NJ, USA). HEPES was purchased from Mallinckrodt Baker, Inc. (Paris, USA). Tissue culture grade sodium bicarbonate, sodium carbonate, sodium chloride, sodium dihydrogen phosphate, and potassium chloride were purchased from Riedel-deHaen (Seelze, Germany). dNTP and MMLV reverse transcriptase were purchased from Promega (Madison, Wis, USA). Taq was purchased from ABgene (Surrey, UK). Donkey antirabbit IgG conjugated with horseradish peroxidase were purchased from Amersham International (Arlington Heights, Ill, USA). Antibody against β-actin was purchased from Cell Signaling (Beverly, USA). Antibody against StAR was a generous gift from Dr. Strauss (University of Pennsylvania Medical Center, USA). Charcoal was purchased from Showa Chemical Inc. (Tokyo, Japan). [3H] progesterone used for radioimmunoassay was purchased from Dupont-New England Nuclear (Boston, USA). Antiserum to progesterone was a kind gift from Dr. Paulus S. Wang (National Yang Ming University, Taipei, Taiwan).

2.2. Cell Culture. The MA-10 cell line was a gift from Dr. Mario Ascoli (The University of Iowa, Iowa City, USA) and is maintained at 37°C in a humified environment containing 95% air and 5% CO₂ for all the following experiments. MA-10 cells (5 × 10⁵ cells/100 μL medium) or (6 × 10⁵ cells/2 mL medium) were plated into 96-well plates or 6 cm dish grown for 24 hr in Waymouth medium containing 10% fetal bovine serum, respectively. The medium was removed and the cells were washed twice with 1X PBS, and then treated with various concentrations of cordycepin in serum free Waymouth medium for indicated time periods. The cells were then isolated for total protein. The expression of target protein was determined by Western blot analysis. Cytotoxicity assay and cell morphological analysis of the MA-10 cells were determined by MTT assay. The media were withdrawn and progesterone levels were determined by radioimmunoassay. Finally, the adenosine receptor subtypes mRNA expression were performed by RT-PCR.

2.3. Morphology Study. MA-10 cells were seeded in 96-well plate (Techno Plastic Products AG, Trasadingen, Switzerland) containing 5 × 10⁴ cells with 100 μL serum medium in each well. After 70–80% confluence, cells were treated without or with 100 μM and 1 mM cordycepin for 24 hr, respectively. Cell morphology was then observed and recorded under light microscopy (Olympus, CK40). Apoptosis was characterized by the loss of cellular contact with the matrix and the appearance of plasma membrane blebbing.

2.4. MTT Cytotoxicity Assay. Cordycepin-induced MA-10 cells cytotoxicity was determined by measuring mitochondrial succinate dehydrogenase activity using a modification of the MTT assay. After MA-10 cells reach 70%–80% confluence, cells were treated with serum free medium containing 100 μM and 1 mM cordycepin for indicated time points (24 and 48 hr). MTT was added to wells (0.5 mg/mL final concentration) after time points of culture at 37°C in a 5% CO₂ humidified atmosphere in the presence of the desired reagents. Mitochondrial dehydrogenases of viable cells will convert MTT into a color-dense formazan. Four hours later, the DMSO was added in wells to dissolve the formazan. The DMSO solutions were added and the absorbance was measured at 590 nm by an ELISA reader (VersaMax, MDS Inc., Toronto, Canada).

2.5. DNA Fragmentation Assay. Cells (1 × 10⁵) were lysed in a 0.6 mL cell lysis solution containing 20 mM Tris-HCl, 10 mM EDTA, pH 8.0 and 0.3% Triton X-100. DNA was extracted with 0.6 mL phenol/chloroform (1:1), and the mixture was centrifuged at 12,500 rpm for 10 min. DNA in the aqueous phase was extracted with phenol/chloroform...
(1:1) again. The aqueous (DNA containing) phase was mixed with isopropanol at −20°C overnight. After centrifugation, DNA pellets were washed with 70% ethanol and air-dried. DNA pellets were dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), and RNase A (3 mg/mL) was added to remove RNA at 37°C for 30 min. DNA electrophoresis was carried out in 2% agarose gel. The gel was stained with ethidium bromide. DNA fragments were visualized by exposing the gel to UV light.

2.6. Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Total RNA was isolated from MA-10 cells using Trizol reagent as recommended by the manufacturer (Invitrogen, Carlsbad, Calif, USA). Reverse transcription was performed in a mixture containing 5 μM random primer, 200 μM dNTP, 2 U/μL MMLV reverse transcriptase together with 5 μL tRNA as the template. The corresponding buffer was performed at 42°C for 90 min followed by 95°C for 10 min. PCR was performed in a mixture containing 2 μL 10X PCR buffer, 0.4 μL 10 mM dNTP, 0.4 μL 20 mM specific forward and reverse primers (primer sequence and corresponding sequence of specific genes were listed in Table 1), 14.7 μL ddH2O, 0.1 μL 0.5 U Taq with 2 μL RT product as template for each reaction. Thermocontrolling program was set up as the following: denature at 95°C for 30 sec, annealing at 55°C for 30 sec, elongation at 72°C for 30 sec with another 5 min of elongation at 72°C. The whole mixture was subjected to 30 cycles for amplification of L19, 34 cycles for amplification of A1-AR, 34 cycles for amplification of A2A-AR and A2B-AR and 38 cycles for amplification of A3-AR. The PCR product was then separated on a 1.5% agarose gel at 120 V for 30 min in 1X TBE buffer (0.09 M Tris, 0.09 M boric acid, 0.001 M EDTA, pH 8.0). The gel was then stained with ethidium bromide for 10 min and destained with mili-Q water. The gel image was captured by using Labwork imager system (Digital CCD Camera, Hamamtsu Photonics system, Bridgewater, USA).

2.7. Radioimmunoassay (RIA). Media from cultures with different treatments were harvested. Twenty μL of sample was loaded into a glass tube and 100 μL of each of progesterone antiserum and 3H progesterone were loaded. Equilibrium reaction occurred at 37°C for 30 min and was stopped by putting the tubes in ice. Charcoal was added into the tubes at 4°C for 15 min and centrifuged for 10 min in order to spin down the charcoal-3H progesterone complex. The supernatant was poured into 2 mL of scintillation fluid and samples would be counted in a β-counter (LS 5000TA, Beckman Inc., Fullerton, Calif, USA).

2.8. Immunoblot Analysis. 6.0 × 105 cells were cultured in 6 cm dish. After treatment, cells were rinsed with cold PBS. Then, the cells were harvested by 100 μL lysis buffer (20 mM Tris-base, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Sodium pyrophosphate, 1 mM beta-Glycerolphosphate, 1 mM Na3VO4). The cell lysate was subjected to centrifugation at 12,000 × g for 12 min at 4°C. The supernatant was stored at −20°C until used. The protein concentration was determined by Lowry method [24]. Total proteins were separated in 12.5% SDS-PAGE. Electrophoresis was performed in SDS-PAGE running buffer (24 mM Tris/HCl, 0.19 M glycine, 0.5% SDS, pH 8.3). The proteins were transferred to polyvinylidene difluoride membranes (PVDF) in transfer buffer (20 mM Tris/HCl, 150 Mm glycine, 10% methanol, 0.05% SDS). The PVDF membrane with protein on it was incubated in blocking buffer (TBS buffer containing 5% Carnation non-fat dry milk and 0.1% Tween-20) at room temperature for an hour. After washing, the membrane would be incubated in primary antibodies StAR at 1:2500 dilutions overnight at 4°C. The membrane would be washed three times (10 min each) with TBS containing 0.1% Tween-20. It was then incubated for an hour at room temperature with fresh blocking buffer containing the secondary antibody, antirabbit IgG. The membrane was washed and the signal detected by using the Renaissance chemiluminescence reagent. The desired protein was quantititated by UVP EC3 Imaging System (Upland, Calif, USA). The amount of β-actin in each lane was detected and quantified as well in order to normalize the expression of target protein.

2.9. Transient Transfection and Luciferase Assays. The 5′-flanking regions (−1278/+32) of the mouse StAR gene were cloned into the pGL3 basic vector (Promega Corp., Madison, Wis, USA), upstream of a luciferase reporter gene utilizing the XhoI and HindIII sites. The plasmid pSV-Galactosidase control vector (Promega Corp.) was used to normalize transfection efficiency. Plasmids were transfected using Lipofectamine 2000 (Invitrogen 11668-019, Invitrogen Corp., Calif, USA). In brief, 1.2 × 105 cells/500 μL medium were cultured in either 24-well plates to 65−75% confluency and transfected using 0.5 μg of plasmid in the presence of 0.5 μg of pSV-Galactosidase control vector. After 6 hr of transfection, MA-10 cells were followed by rising and incubation in serum-free Waymouth medium for 18 hr. After

| Table 1: Sequence of primers used for reverse transcription-polymerase chain reaction (RT-PCR). |
|-----------------------------------------------|
| **Sequence (5′ to 3′)** | **PCR size** |
| L19 | F GAA ATC GCC AAT GCC AAC TC R TCT TAG ACC TGC GAG CCT CA | 405 b.p. |
| A1-AR | F CGG GAT CCT ACA TCT CCT TCC AGG R GGA ATT CAG TAG GTG GCC CCA ATG | 219 b.p. |
| A2A-AR | F CGG GAT CGG TCC CTG GCC ATC ATC GT R GGA ATT CGA TCC GTG AGG GTG AGA T | 177 b.p. |
| A2B-AR | F CGG GTA CCC CTC GAG TGC ATT ACA GA R CCG CCG AAA CCT TTA TAC CTG AGC | 216 b.p. |
| A3-AR | F CGG GAT CCC GTT CCG TGG TCA GA | 384 b.p. |
| | F CCG GAT CCC AGG CAG CTT AGA CAA TAG G | 384 b.p. |
medium was changed, cells were then treated with cordycepin for another 12 hr. Luciferase assays were performed using the Luciferase Reporter Assay System according to the manufacturer’s instructions (Promega Corp., Madison, Wis, USA). Briefly, after treatment cells were washed with 1X PBS and 200 μL of the 1X passive lysis buffer (Dual-Luciferase Reporter Assay System, Promega E1910, Promega Corp., Madison, Wis, USA) was added to the plates. The cellular debris was pelleted by centrifugation at 12,000 × g at 4 °C, and the 20 μL supernatant was measured for 50 μL Luciferase Assay Buffer (Dual-Luciferase Reporter Assay System, Promega E1910, Promega Corp., Madison, Wis, USA) in a MiniLumat Luminometer (Turner Designs Corp., Sunnyvale, Calif, USA).

2.10. Statistical Analysis. Each data point in the figures represents the mean ± SEM of three or four separate experiments. Statistically significant differences between treatments and controls were determined by one-way ANOVA and then least significance difference (LSD) or with t-test comparison procedure. Statistical significance was set at P < .05.

3. Results

3.1. Effects of Cordycepin on Steroidogenesis in MA-10 Mouse Leydig Tumor Cells. To test the hypothesis that cordycepin influences the production of steroid hormone in MA-10 mouse Leydig tumor cells; we initially determined the effect of cordycepin on the production of progesterone. MA-10 cells were incubated with different dosages (1, 10, 100 μM, and 1 mM) of cordycepin for 24 hr. Results showed that the progesterone production induced by 100 μM cordycepin was more than 3 folds significantly compared to the control (217.5 ± 101.7 versus 675.9 ± 185.4 pg/μg protein; P < .05) (Figure 1(a)). As shown in Figure 1(b), cordycepin at 100 μM significantly stimulated progesterone to a maximum at 24 hr (P < .05). According to the results, 100 μM cordycepin for 24 hr treatment was used to investigate the possible cellular mechanism.

3.2. RT-PCR Analysis for Detection of A1, A2A, A2B, and A3 Adenosine Receptor mRNA Transcripts in MA-10 Mouse Leydig Tumor Cells. It has been reported that cordycepin could inhibit lung carcinoma and melanoma cell growth by stimulating A3-AR [25, 26]. We hypothesized for the presence of functional adenosine receptor subtypes that involved in cordycepin-induced steroidogenesis in MA-10 cells. Thus, mRNA expressions of all four AR subtypes, A1, A2A, A2B, and A3, with cordycepin treatment in MA-10 cells were analyzed by RT-PCR. The results showed that cordycepin (100 μM and 1 mM) could change the mRNA expression among four AR subtypes (Figure 2(a)). The normalized results showed that the treatment of 1 mM cordycepin for 24 hr upregulated the expression of A1-AR mRNA for about 1.5 fold (P < .05) (Figure 2(b)). Cordycepin (1 mM) upregulated the expression of A2A-AR mRNA for about 2 folds (P < .05) (Figure 2(c)). Cordycepin at 1 mM would also upregulate the expression of A3-AR mRNA for about 3 folds (P < .05) (Figure 2(e)). However, both 100 μM and 1 mM cordycepin would downregulate A2B-AR mRNA expression by 60% and 80%, respectively (P < .05) (Figure 2(d)).

3.3. A1, A2A, A2B, and A3 AR Were Involved in Cordycepin-Induced Steroidogenesis in MA-10 Mouse Leydig Tumor Cells. By using AR agonists (1~100 μM) to treat MA-10 cells for 24 hr, the results showed that A1-, A2A-, A2B-, and A3-AR agonists could stimulate progesterone production in MA-10 mouse Leydig cells (P < .05) (Figures 3(a)–3(d)). Compared to the control, A1-AR agonist could significantly stimulate progesterone production and reach 4.1 folds by 100 μM CPA (P < .05) (Figure 3(a)). A2A-AR agonist could significantly stimulate progesterone production and reach 6.8 and 7.9 folds by 10 and 25 μM CGS-21680, respectively, (P < .05) (Figure 3(b)). A2B-AR agonist could
Figure 2: Characterization of A1, A2A, A2B, and A3 AR mRNA expression in MA-10 mouse Leydig tumor cells. MA-10 cells ($1 \times 10^6$) were cultured in Waymouth medium to 80% confluence, and then the total RNA were extracted and the expression of adenosine receptor subtypes mRNA were analyzed by RT-PCR. (a) shows A1, A2A, A2B, and A3 AR mRNA expression in response to cordycepin at different dosages (100 μM and 1 mM) for 24 hr. L19 is the housekeeping gene used as an internal control. (b) shows the integrated optical density (IOD) of A1, A2A, A2B, and A3 AR mRNA expression after normalization with L19. Each data point in the figure represents the mean ± SEM of three separate experiments. Asterisk * ($P < .05$) above the bars indicates significant difference compared with control.

Significantly stimulate progesterone production and reach 7.6, 8.9, and 9.8 folds by 1, 10, and 100 μM NECA, respectively, ($P < .05$) (Figure 3(c)). A2-AR agonist could significantly stimulate progesterone production and reach 10.5 and 24.7 folds by 10 and 50 μM IB-ECA, respectively ($P < .05$) (Figure 3(d)). On the other hand, cordycepin (100 μM) cotreated with A1-AR agonist would significantly decrease CPA-stimulated (100 μM) progesterone production by 47% ($P < .05$) (Figure 3(a)). Cordycepin (100 μM) cotreated with A2B-AR agonist would significantly decrease NECA-stimulated (1, 10 and 100 μM) progesterone production by 70%, 69%, and 47%, respectively, ($P < .05$)
3.4. Effects of Cordycepin on StAR Protein and Promoter Expressions in MA-10 Mouse Leydig Tumor Cells. It has been previously shown that steroidogenesis induced by *Cordyceps sinensis* in MA-10 cells requires de novo protein synthesis [27]. To further understand the mechanism of cordycepin-induced steroidogenesis in MA-10 cells, StAR protein expression was investigated by Western blotting analysis. MA-10 cells were incubated with different dosages (1 ∼ 100 μM) of cordycepin for 3 hr or 100 μM cordycepin for 1, 3, 6, and 12 hr, respectively. Results showed that the expression of StAR protein was not activated by cordycepin with different dosages (Figure 5(a)) and different time treatments (Figure 5(b)) in MA-10 mouse Leydig tumor cells (P > .05).

In addition, MA-10 cells were transiently transfected with plasmid containing luciferase gene with 5’-flanking StAR promoter constructs between −1.3 k to +32 regions, and cordycepin (100 μM) was added for 12 hr treatment. Results of 5’-deletion promoter analysis indicated that cordycepin did not increase StAR promoter activity (P > .05) (Figure 5(c)). Taken together, these results suggest that StAR protein and StAR promoter might not be involved in the cordycepin-induced steroidogenesis in MA-10 cells.

3.5. Effects of Cordycepin and Adenosine on Cell Death in MA-10 Mouse Leydig Tumor Cells. According to our previous (Figure 3(c)). Cordycepin (100 μM) cotreated with A3-AR agonist would significantly decrease IB-MECA (50 μM)-stimulated progesterone production by 33% (P < .05) (Figure 3(d)). However, cordycepin (100 μM) cotreated with A2A-AR agonist would not affect CGS-21680-stimulated progesterone production (P > .05) (Figure 3(b)). These results demonstrated that cordycepin could regulate AR subtype expressions to stimulate progesterone production in MA-10 cells. To further understand the mechanism of functional AR subtypes that involved in the cordycepin-induced steroidogenesis in MA-10 mouse Leydig tumor cells, selective A1-, A2A-, A2B-, and A3-AR subtype antagonists (10 nM ∼ 1 μM) were used to cotreat with cordycepin for 24 hr. The results showed that A1-, A2A-, A2B-, and A3-AR antagonists did not have inhibitory effect on cordycepin-induced progesterone production in MA-10 cells (P > .05) (Figures 4(a) ∼ 4(d)).
Figure 4: Effects of AR antagonists on cordycepin-induced steroidogenesis in MA-10 mouse Leydig tumor cells. MA-10 cells (5,000 cells/well) were treated with different dosage (10 nM~1 μM) of A1, A2A, A2B, and A3 AR antagonists, which were (a) DPCPX, (b) Caffeine, (c) MRS-1754, and (d) MRS-1191 in the absence or presence of 100 μM cordycepin for 24 hr. Media were collected and assayed for progesterone production by RIA. Each data point in the figure represents the mean ± SEM of three independent experiments with triplicates in each treatment. Asterisk *(P<.05) above the bars indicates significant difference compared with control.

studies, cordycepin has antitumor activity in OECM-1 oral cancer and MA-10 mouse Leydig tumor cell lines [3, 28]. We hypothesized that cordycepin, an adenosine analogue, might act through AR to induce cell death in MA-10 mouse Leydig tumor cells. Thus, the death effects of cordycepin and adenosine on MA-10 cell line was investigated by culturing MA-10 cells with different dosage of adenosine (10 μM~10 mM) and cordycepin (100 μM~1 mM) for comparison. MTT assay showed that 1, 2, 5, and 10 mM adenosine significantly decreased MA-10 cell viability to 78%, 65%, 43%, and 39% (*P < .05), and cordycepin (100 μM and 1 mM) significantly decreased MA-10 cell viability to 44% and 13% (*P < .05) for 48 hr treatment, respectively (Figure 6(a)). DNA fragmentation was also observed in the MA-10 cells with 10 mM adenosine after 48 hr treatment (Figure 6(b)). The results are comparable regarding the cell death effects between cordycepin and adenosine on MA-10 cells.

3.6. A1, A2A, A2B, and A3 AR Were Involved in Cordycepin-Induced Cell Death in MA-10 Mouse Leydig Tumor Cells. Previous data demonstrate that expressions of AR subtypes, A1, A2A, A2B, and A3 mRNA are found in MA-10 cells, and their expression could be modulated by the presence of cordycepin. To investigate whether cordycepin-induced apoptosis was mediated via adenosine receptors on MA-10 mouse Leydig tumor cells, cells were treated with A1-, A2A-, A2B-, and A3-AR agonists (CPA, CGS-21680, NECA and IB-MECA) for 24 hr, respectively. Results show that some MA-10 cells appeared rounded-up phenomenon with floating and membrane-blebbing after 24 hr cordycepin (100 μM and 1 mM) treatment (Figure 7(a)). In addition, MA-10 cells treated with A1-, A2A-, A2B-, and A3-AR agonists (100 μM, 25 μM, 100 μM, and 50 μM, resp.) for 24 hr also induced cells to have rounded-up phenomenon with floating cells (Figure 7(b)). Cotreatment of cordycepin (100 μM and 1 mM) with A1-, A2A-, and A2B-agonists (100 μM, 25 μM, 100 μM, and 50 μM, resp.) for 24 hr also induced cells to have rounded-up phenomenon with floating and membrane-blebbing. Interestingly, A3-AR agonist (50 μM) cotreated with cordycepin (100 μM and 1 mM) for 24 hr would let some MA-10 cell recover back to polygonal shape, which was similar to the control group (Figure 7(c)). MTT cytotoxicity assay was further employed to assess cell viability (Figure 7(d)). Compared to the control, A1-AR agonist, CPA, at 100 μM
caused a significant reduction in cell viability to 73.8 ± 5.2% (P < .05). A2A-AR agonist, CGS-21680, at 10 μM and 25 μM caused a significant reduction in cell viability to 84.9 ± 2.4% and 78.4 ± 4.0%, respectively (P < .05). A2B-AR agonist, NECA, at 10 μM and 100 μM caused significant reductions in cell viability to 82.9 ± 1.5% and 72.9 ± 2.6%, respectively (P < .05). A3-AR agonist, IB-MECA, at 50 μM caused a significant reduction in cell viability to 75.7 ± 2.4% (P < .05). These results showed that A1-, A2A-, A2B-, and A3-AR agonists significantly reduced MA-10 cell viability, respectively (Figure 7(d)) (P < .05). Besides, cordycepin alone (100 μM and 1 mM) significantly decreased MA-10 cell viability approximately to 60% and 40%, respectively, after 24 hr treatment (Figure 7(e)) (P < .05). However, A1-, A2A-, and A2B-AR agonists plus cordycepin treatments did not have any additive effects on MA-10 cell death, respectively (Figure 7(e)) (P > .05). But, A3-AR agonist (50 μM) cotreated with cordycepin (100 μM or 1 mM) would reverse MA-10 cell viability back to 81.6 ± 9.6% or 61.6 ± 7.8%, respectively (Figure 7(e)). These results showed that A1-, A2A-, A2B-, and A3-AR might be very important regarding the antitumor effects of cordycepin in MA-10 cells.

3.7. AR Antagonists Could Prevent Cordycepin-Induced Cell Death in MA-10 Mouse Leydig Tumor Cells. In order to confirm whether cordycepin-induced apoptosis was mediated via AR on MA-10 mouse Leydig tumor cells, cells were treated with cordycepin (100 μM and 1 mM) plus A1-, A2A-, A2B-, and A3-AR antagonists (DPCPX, Caffeine, MRS1754 and MRS1911) for 24 hr, respectively. All A1-, A2A-, A2B, and A3-AR antagonists could let cordycepin-treated MA-10 cells recover back to polygonal shape, which is similar to the cells in control group (Figure 8(a)). In MTT assay, the cotreatment of 100 μM cordycepin with 1 μM A1-, A2A-, A2B-, and A3-AR antagonists could significantly reverse cell viability to 90.6% ± 3.8%, 89.2% ± 4.8%, 86.7% ± 1.9% and 83.3% ± 5.7%, respectively (P < .05) (Figure 8(b)). However, the cotreatment of 1 mM cordycepin

![Figure 5](image-url)
Evidence-Based Complementary and Alternative Medicine 9

Adenosine dosage

0 20 40 60 80 100 120

10 μM 100 μM 1m M 2m M 5m M 10 mM

Cell viability (%)

Control 1m MCordy.

∗∗∗∗

(a)

Experiments

M I II III IV

3054 2036 1636 1080

517 396 344 296 220

(b.p.)

(b)

Figure 6: Effects of cordycepin and adenosine on cell death in MA-10 mouse Leydig tumor cells. MA-10 cells were cultured in medium without or with adenosine (10 μM~10 mM), 100 μM and 1 mM cordycepin for 48 hr (a). MTT assay was performed to assess cell viability. Data represent the mean ± SEM of four separate experiments. Asterisk (*) (P < .05) above the bars indicates significant difference compared with control. (cordy. = cordycepin). (b) Gel electrophoresis of a 1 kb DNA ladder marker (lane M) or DNA isolated from MA-10 cells that were cultured in the presence of 10 mM adenosine for 48 hr. DNA was visualized by ethidium bromide staining and photographed under UV illumination. Experiments were performed four times (Exp. I–IV) with similar results.

with A1-, A2A-, A2B-, and A3-AR antagonists did not reverse cell viability (Figure 8(c)). These results indicate that the apoptotic effects of cordycepin on MA-10 cells could be mediated by adenosine receptors.

4. Discussion

In this study, we demonstrate that cordycepin, a pure substance isolated from the Cordyceps sinensis, could stimulate steroidogenesis in MA-10 mouse Leydig tumor cells. Besides, cordycepin could induce the antitumor effect possibly through adenosine receptors in MA-10 mouse Leydig tumor cells.

First, we found that cordycepin increased the expression of A1- and A2A-AR mRNA but decreased the expression of A2B-AR mRNA at 24 hr treatment. Under microscopic observation, we found that cordycepin-treated MA-10 cells exhibited cellular shrinkage and membrane blebbing, and finally cells detached from the dish. By MTT and DNA ladder assays, adenosine also significantly reduced MA-10 cell viability in a dose-dependent manner and induced DNA fragmentation. The effective concentration (EC50) of adenosine which could cause 50% inhibition of MA-10 cells growth was 5 mM after 48 hr treatment. However, we observed that the death effect of cordycepin was somewhat greater than adenosine in the same concentration (100 μM and 1 mM). These phenomena indicate that the apoptotic effect by adenosine in MA-10 cells was comparable.

Nakamura and coworkers have demonstrated that cordycepin inhibited lung carcinoma cells and melanoma cells growth by stimulating A3-AR [25, 26]. Many evidences have also illustrated that A1- and A2A-AR expression mediated cell death by inducing apoptosis in breast carcinoma cells, astrocytoma cells, mouse thymocytes [29–31]. In this study, we showed that cordycepin could significantly stimulate the expression of A3-AR mRNA in cordycepin-treated MA-10 cells. Moreover, this effect also occurred in A1-AR and A2A-AR mRNA expressions. In addition, we also demonstrated that cordycepin induced MA-10 mouse Leydig tumor cell apoptosis through caspase-9 and caspase-3 pathways [28]. These data suggested that AR might participate in cordycepin-induced apoptosis pathway in MA-10 mouse Leydig cells.

We continued to investigate the AR agonists to cotreat with cordycepin in MA-10 cells. We found that A3-AR agonists could significantly rescue cordycepin-induced apoptosis in MA-10 cells. Many reports indicate that adenosine displays contradictory effects such as the induction of cell apoptosis or stimulation of cell proliferation [32, 33]. It has been reported that the A3-AR agonist (CL-IB-MECA) reduced apoptosis in human astrogliaoma D384 cells [34]. In fact, some evidences have shown that adenosine via A1-AR- and A3-AR-mediated cytoprotection involves phospholipase C, PKC, and p38 MAPK pathways, and reduced ROS production in cardiomyocytes [35–37]. In this study, we demonstrated that activation of AR would induce apoptosis in MA-10 cells. However, activation of different subtypes of
Figure 7: A1, A2A, A2B, and A3 AR were involved in cordycepin-induced cell death in MA-10 mouse Leydig tumor cells. MA-10 cells were treated with A1, A2A, A2B, and A3 AR agonists in the absence or presence of cordycepin for 24 hr. (a) shows that MA-10 cells were incubated in the absence or presence of cordycepin (100 μM and 1 mM) for 24 hr. (b) shows that MA-10 cells were incubated in AR agonists (A1 100 μM, A2A 25 μM, A2B 100 μM, and A3 50 μM) for 24 hr. (c) shows that MA-10 cells were incubated in cordycepin (100 μM or 1 mM) plus AR agonists (A1 10 μM, A2A 10 μM, A2B 10 μM, and A3 50 μM) for 24 hr. Cell morphology was observed and recorded under light microscopy (Olympus, CK 40). Note the same magnification (200x) among Figures. Arrowhead (▲) indicates rounded-up cells and/or membrane-blebbed cells. MA-10 cells (5,000 cells/well) were treated with different dosages (1 ∼ 100 μM) of A1-, A2A-, A2B-, and A3-AR agonist in the absence (d) or presence of cordycepin (100 μM and 1 mM) for 24 hr (e). MTT assay was used to assess cell viability, which was proportional to absorbance at 590 nm. Each data point in the Figure represents the mean ± SEM of four independent experiments with triplicates in each treatment. Asterisk (*) (P < .05) above the bars indicates significant difference compared with control. #(P < .05) above the bars indicates significant difference compared with cordycepin alone treatment group (C: cordycepin).
AR could trigger apoptosis/survival pathway in MA-10 cells, which must be further investigated.

Recent reports demonstrated that adenosine receptor antagonists can resume cell viability on toxicant drug-induced apoptosis in thyroid cancer cells [38, 39]. We used the selective AR antagonists to cotreat with cordycepin in MA-10 cells. We also demonstrated that A1−, A2A−, A2B−, and A3−AR antagonist could significantly rescue 100 μM cordycepin-induced apoptosis in MA-10 cells. These results indicate that the apoptotic effects of cordycepin on MA-10 cells could be mediated by AR. However, 1 mM cordycepin cotreated with adenosine antagonists could not reverse cell viability, but even promote cell death. Recent developments of potent and selective antagonists of AR subtypes have been valuable for further defining the physiological effects of the various AR subtypes. Moreover, there are substantial species differences in the affinity of these compounds, and these selective compounds may fairly potent as antagonists of another AR subtypes [40].

It has been shown that adenosine-stimulated steroidogenesis might be involved in the A2A− and A2B−AR and phosphorylation of MAPK ERK 1/2 signal pathway in rat adrenal cells [41]. Moreover, it is proposed that ligand binding results in a change in receptor state from an inactive to an active state will ultimately elicit its biological response based on the receptor’s conformation [42]. In this model,
agonists are thought to have selective binding affinity for the preexisting resting and active states or can induce a conformational change to a different receptor state and effects binding affinity of a ligand [43]. In the present study, cordycepin cotreated with $A_{2B}$-AR agonist (NECA) would significantly decrease NECA-stimulated progesterone production. It is probable that cordycepin may bind with other receptors and induce conformation change to effect binding affinity of $A_{2B}$-AR agonist. This result is consistent with the observation that cordycepin (100 μM) decreased the expression of $A_{2B}$-AR mRNA at 24 hr treatment. Although cordycepin (100 μM) did not affect the expression of $A_{1}$- and $A_{3}$-AR mRNA, cordycepin cotreated with $A_{1}$- and $A_{3}$-AR agonist (CPA and IB-MECA) also significantly decreased their progesterone production. On the other hand, cordycepin did not affect the $A_{2A}$-AR agonist (CGS-21680)-stimulated progesterone production. It is reasonable that cordycepin may compete with CGS-21680 in the same binding site of $A_{2A}$-AR to stimulate progesterone production. Here, we demonstrated that activation of $A_{1}$-, $A_{2A}$-, $A_{2B}$-, and $A_{3}$-AR could induce steroidogenesis in MA-10. However, we used the AR antagonists to cotreat with cordycepin, and results illustrated huge variations. AR antagonists only slightly increased progesterone production than control group in MA-10 cells, which may decrease the accuracy. More experiments should be conducted to decrease the inconsistence.

Steroid production in Leydig and granulosa cells are regulated by various factors, including cAMP/PKA-dependent [44], mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 (MAPK ERK 1/2) [45, 46], and protein kinase C (PKC) signaling pathways [47, 48]. These kinases modulate cellular processes by phosphorylations. The family of MAPKs includes extracellular regulating kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38, with each MAPK signaling pathway consisting of at least three components, a MAPK kinase kinase (MAP3k), a MAPK kinase (MAP2k), and a MAPK. Some reports have shown the stimulatory effects of MAPK ERK 1/2 on steroidogenesis [49, 50], and the others have demonstrated the inhibitory effects on steroidogenesis [51, 52]. PKC signaling pathway can be activated by signals such as increases in the concentration of diacylglyceride (DAG), phospholipase C (PLC), or Ca$^{2+}$ [53]. Recent reports indicate that DAX-1 gene interplay between the PKA/PKC signaling pathways and represses expression of StAR protein and steroidogenesis [54]. It is well established that StAR protein is essential for steroidogenesis, and that ERK 1/2 phosphorylation driven by mitochondrial PKA will induce StAR protein expression and then steroidogenesis [46]. The previous data showed that cordycepin upregulates the expression of StAR mRNA and StAR protein to induce steroidogenesis through the PKA signaling pathway in normal mouse Leydig cells [55]. It has also been documented that the downstream effectors of PKA signaling pathway include several transcription factors [56]. However, our results indicated that cordycepin could not induce StAR protein and StAR promoter expressions in MA-10 cells. Our data are somewhat inconsistent to several studies that steroidogenesis could be trigger by cAMP and StAR-independent pathways [57–59]. Therefore, it is possible that the cordycepin could possibly activate MAPK-ERK 1/2 and PKC pathways without increasing of StAR promoter and StAR protein expression to induce steroidogenesis in MA-10 cells, which will be worth to further investigate.

In conclusion, the present studies demonstrate that cordycepin is one of the active constituent of Cordyceps sinensis, which can stimulate progesterone production in MA-10 cells. Meanwhile, cordycepin could also activate AR and simultaneously induce steroidogenesis and apoptosis in MA-10 mouse Leydig tumor cells.

Acknowledgment

This work was supported by National Science Council Grants NSC98-2320-B-006-016 (to B.-M. Huang), Taiwan.

References

[1] X. Zhou, Z. Gong, Y. Su, J. Lin, and K. Tang, “Cordyceps fungi: natural products, pharmacological functions and developmental products,” Journal of Pharmacy and Pharmacology, vol. 61, no. 3, pp. 279–291, 2009.
[2] Z. Q. He, J. Li, and D. Y. Cheng, “Effect of cordycepin on apoptosis and cell cycle in HeLa cells,” Zhonghua Zhong Liu Za Zhi, vol. 31, no. 4, pp. 258–259, 2009.
[3] W. C. Wu, J. R. Hsiao, Y. Y. Lian, C. Y. Lin, and B. M. Huang, “The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 103–111, 2007.
[4] H. Thomadaki, C. M. Tsipalis, and A. Scorilas, “Polyadenylate polymerase modifications in human epithelial cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction,” Biological Chemistry, vol. 386, no. 5, pp. 471–480, 2005.
[5] H. Thomadaki, A. Scorilas, C. M. Tsipalis, and M. Havredaki, “The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 2, pp. 251–265, 2008.
[6] Y. L. Huang, S. F. Leu, B. C. Liu, C. C. Sheu, and B. M. Huang, “In vivo stimulatory effect of Cordyceps sinensis mycelium and its fractions on reproductive functions in male mouse,” Life Sciences, vol. 75, no. 9, pp. 1051–1062, 2004.
[7] Y. C. Chen, Y. L. Huang, and B. M. Huang, “Cordyceps sinensis mycelium activates PKA and PKC signal pathways to stimulate steroidogenesis in MA-10 mouse Leydig tumor cells,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 1, pp. 214–223, 2005.
[8] H. Y. Yang, S. F. Leu, Y. K. Wang, C. S. Wu, and B. M. Huang, “Cordyceps sinensis mycelium induces MA-10 mouse Leydig tumor cell apoptosis by activating the caspase-8 pathway and suppressing the NF-kB pathway,” Archives of Andrology, vol. 52, no. 2, pp. 103–110, 2006.
[9] H. K. Ghayee and R. J. Auchus, “Basic concepts and recent developments in human steroid hormone biosynthesis,” Reviews in Endocrine and Metabolic Disorders, vol. 8, no. 4, pp. 289–300, 2007.
[10] N. Martinat, P. Crépieux, E. Reiter, and F. Guillon, “Extra-cellular signal-regulated kinases (ERK) 1,2 are required for luteinizing hormone (LH)-induced steroidogenesis in primary Leydig cells and control steroidogenic acute regulatory (StAR)
expression,” *Reproduction Nutrition Development*, vol. 45, no. 1, pp. 101–108, 2005.

[11] P. R. Manna, J. Kero, M. Tena-Sempere, P. Pakarinen, D. M. Stocco, and I. T. Huhtaniemi, “Assessment of mechanisms of thyroid hormone action in mouse Leydig cells: regulation of the steroidogenic acute regulatory protein, steroidogenesis, and luteinizing hormone receptor function,” *Endocrinology*, vol. 142, no. 1, pp. 319–331, 2001.

[12] F. Arakane, T. Sugawara, H. Nishino et al., “Steroidogenic acute regulatory protein (StAR) retains activity in the absence of its mitochondrial import sequence: implications for the mechanism of StAR action,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 24, pp. 13731–13736, 1996.

[13] D. M. Stocco, “Tracking the role of a STAR in the sky of the new millennium,” *Molecular Endocrinology*, vol. 15, no. 8, pp. 1245–1254, 2001.

[14] D. M. Stocco, “The role of the STAR protein in steroidogenesis: challenges for the future,” *Journal of Endocrinology*, vol. 164, no. 3, pp. 247–253, 2000.

[15] N. Cherradi, G. Defaye, and E. M. Chambaz, “Characterization of the 3β-hydroxysteroid dehydrogenase activity associated with bovine adrenocortical mitochondria,” *Endocrinology*, vol. 134, no. 3, pp. 1358–1364, 1994.

[16] S. Sulimovici, B. Bartoo, and B. Lunenfeld, “Localization of 3β hydroxysteroid dehydrogenase in the inner membrane subfraction of rat testis mitochondria,” *Biochimica et Biophysica Acta*, vol. 321, no. 1, pp. 27–40, 1973.

[17] B. B. Fredholm, G. Arslan, L. Halldner, B. Kull, G. Schulte, and W. Wasserman, “Structure and function of adenosine receptors and their genes,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 362, no. 4-5, pp. 364–374, 2000.

[18] S. M. Reppert, D. R. Weaver, J. H. Stehle, and S. A. Rivkees, “Molecular cloning and characterization of a rat A3 adenosine receptor that is widely expressed in brain and spinal cord,” *Molecular Endocrinology*, vol. 5, no. 8, pp. 1037–1048, 1991.

[19] Q. Y. Zhou, C. Li, M. E. Olah, R. A. Johnson, G. L. Stiles, and O. Civelli, “Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 16, pp. 7432–7436, 1992.

[20] S. A. Rivkees and S. M. Reppert, “RFL9 encodes an A(2b)-adenosine receptor,” *Molecular Endocrinology*, vol. 6, no. 10, pp. 1598–1604, 1992.

[21] J. H. Stehle, S. A. Rivkees, J. J. Lee, D. R. Weaver, J. D. Deeds, and S. M. Reppert, “Molecular cloning and expression of the cDNA for a novel A3-adenosine receptor subtype,” *Molecular Endocrinology*, vol. 6, no. 3, pp. 384–393, 1992.

[22] S. C. Chow, G. E. N. Kass, and S. Orrenius, “Purines and their roles in apoptosis,” *Neuropharmacology*, vol. 36, no. 9, pp. 1199–1156, 1997.

[23] S. F. Leu, S. L. Poon, H. Y. Pao, and B. M. Huang, “The in vivo and in vitro stimulatory effects of cordycepin on mouse Leydig cell steroidogenesis,” *Bioscience Biotechnology, and Biochemistry*, vol. 75, no. 4, pp. 723–731, 2011.

[24] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” *The Journal of Biological Chemistry*, vol. 193, no. 1, pp. 265–275, 1951.

[25] K. Nakamura, N. Yoshikawa, Y. Yamaguchi, S. Kagota, K. Shinozuka, and M. Kunitomo, “Antitumor effect of cordycepin (3-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation,” *Anticancer Research*, vol. 26, no. 1, pp. 45–47, 2006.

[26] N. Yoshikawa, S. Yamada, C. Takeuchi et al., “Cordycepin (3'-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycolgen synthase kinase-3β activation and cyclin D1 suppression,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 377, no. 4–6, pp. 591–595, 2008.

[27] B. M. Huang, S. Y. Ju, C. S. Wu, W. J. Chuang, C. C. Sheu, and S. F. Leu, “Cordyceps sinensis and its fractions stimulate MA-10 mouse Leydig tumor cell steroidogenesis,” *Journal of Andrology*, vol. 22, no. 5, pp. 831–837, 2001.

[28] B. M. Huang, C. Y. Jen, C. Y. Lin, and S. F. Leu, “Cordycepin induced MA-10 mouse Leydig tumor cell apoptosis through caspase-9 pathway,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 984537, 11 pages, 2011.

[29] A. Mirza, A. Basso, S. Black et al., “RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis,” *Cancer Biology and Therapy*, vol. 4, no. 12, pp. 1355–1360, 2005.

[30] I. Kiss, H. Oskolás, R. Tóth et al., “Adenosine A receptor-mediated cell death of mouse thymocytes involves adenylyl cyclase and Bim and is negatively regulated by Nur77,” *European Journal of Immunology*, vol. 36, no. 6, pp. 1559–1571, 2006.

[31] K. Sai, D. Yang, H. Yamamoto et al., “An adenosine receptor signal and AMPK involving caspase-9/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma cell death,” *NeuroToxicology*, vol. 27, no. 4, pp. 458–467, 2006.

[32] M. Saito, T. Yaguchi, Y. Yasuda, T. Nakano, and T. Nishizaki, “Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A1 adenosine receptors,” *Cancer Letters*, vol. 290, no. 2, pp. 211–215, 2010.

[33] P. Fishman, S. Bar-Yehuda, T. Farbstein, F. Barer, and G. Ohana, “Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors,” *Journal of Cellular Physiology*, vol. 183, no. 3, pp. 393–398, 2000.

[34] O. Björklund, M. Shang, I. Tonazzini, E. Daré, and B. B. Fredholm, “Adenosine A and A receptors protect astrocytes from hypoxic damage,” *European Journal of Pharmacology*, vol. 596, no. 1–3, pp. 6–13, 2008.

[35] R. A. Fenton, L. G. Shea, C. Doddí, and J. G. Dobson, “Myocardial adenosine A1-receptor-activated adenoprotein involves phospholipase C, PKC-ε, and p38 MAPK, but not HSP27,” *American Journal of Physiology*, vol. 298, no. 6, pp. H1671–H1678, 2010.

[36] F. Yang, Y. S. Huang, D. X. Zhang, Z. G. Chu, J. P. Zhang, and Q. Zhang, “Adenosine A receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes,” *Clinical and Experimental Pharmacology and Physiology*, vol. 37, no. 3, pp. 343–349, 2010.

[37] T. C. Zhao and R. C. Kukreja, “Protein kinase C-δ mediates adenosine A receptor-induced delayed cardioprotection in mouse,” *American Journal of Physiology*, vol. 285, no. 1, pp. H1434–H1441, 2003.

[38] S. Morello, A. Porta et al., “CI-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-κB signalling pathway in thyroid cancer cells,” *Journal of Cellular Physiology*, vol. 221, no. 2, pp. 378–386, 2009.

[39] G. Simonis, S. Wiedemann, D. Joachim, C. Weinbrenner, R. Marquetant, and R. H. Strasser, “Stimulation of adenosine A2b receptors blocks apoptosis in the non-infarcted myocardium even when administered after the onset of
infarction,” *Molecular and Cellular Biochemistry*, vol. 328, no. 1-2, pp. 119–126, 2009.

[40] J. Linden, “Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection,” *Annual Review of Pharmacology and Toxicology*, vol. 41, pp. 775–787, 2001.

[41] W. Zhang, J. Li, S. Qiu, J. Chen, and Y. Zheng, “Effects of the exopolysaccharide fraction (EPSF) from a cultivated Cordyceps sinensis on immunocytes of H22 tumor bearing mice,” *Fitoterapia*, vol. 79, no. 3, pp. 168–173, 2008.

[42] J. W. Black and P. Leff, “Operational models of pharmacological agonism,” *Proceedings of the Royal Society of London*, vol. 220, no. 1219, pp. 141–162, 1983.

[43] H. P. Rang, “The receptor concept: pharmacology’s big idea,” *British Journal of Pharmacology*, vol. 147, no. 1, supplement, pp. S9–S16, 2006.

[44] M. T. Dyson, M. P. Kowalewski, P. R. Manna, and D. M. Stocco, “The differential regulation of steroidogenic acute regulatory protein-mediated steroidogenesis by type I and type II PKA in MA-10 cells,” *Molecular and Cellular Endocrinology*, vol. 300, no. 1-2, pp. 94–103, 2009.

[45] Y. M. Lin, C. C. Tsai, C. L. Chung et al., “Fibroblast growth factor 9 stimulates steroidogenesis in postnatal Leydig cells,” *International Journal of Andrology*, vol. 33, no. 3, pp. 545–553, 2010.

[46] C. Poderoso, P. Maloberti, A. Duarte et al., “Hormonal activation of a kinase cascade localized at the mitochondria is required for StAR protein activity,” *Molecular and Cellular Endocrinology*, vol. 300, no. 1-2, pp. 37–42, 2009.

[47] P. R. Manna, S. P. Chandrala, S. R. King et al., “Molecular mechanisms of insulin-like growth factor-I mediated regulation of the steroidogenic acute regulatory protein in mouse Leydig cells,” *Molecular Endocrinology*, vol. 20, no. 2, pp. 362–378, 2006.

[48] Y. Jo, S. R. King, S. A. Khan, and D. M. Stocco, “Involvement of protein kinase C and cyclic adenosine 3′,5′-monophosphate-dependent kinase in steroidogenic acute regulatory protein expression and steroid biosynthesis in Leydig cells,” *Biology of Reproduction*, vol. 73, no. 2, pp. 244–255, 2005.

[49] S. L. Gyles, C. J. Burns, B. J. Whitehouse et al., “ERKs Regulate Cyclic AMP-induced Steroid Synthesis through Transcription of the Steroidogenic Acute Regulatory (StAR) Gene,” *The Journal of Biological Chemistry*, vol. 276, no. 37, pp. 34888–34895, 2001.

[50] S. Das, E. T. Maizels, D. Demanno, E. S. T. Clair, S. A. Adam, and M. Hunziker-Dunn, “A stimulatory role of cyclic adenosine 3′,5′-monophosphate in follicle-stimulating hormone-activated mitogen-activated protein kinase signaling pathway in rat ovarian granulosa cells,” *Endocrinology*, vol. 137, no. 3, pp. 967–974, 1996.

[51] R. Seger, T. Hanoch, R. Rosenberg et al., “The ERK Signaling Cascade Inhibits Gonadotropin-stimulated Steroidogenesis,” *The Journal of Biological Chemistry*, vol. 276, no. 17, pp. 13957–13964, 2001.

[52] K. Tajima, A. Dantes, Z. Yao et al., “Down-regulation of steroidogenic response to gonadotropins in human and rat preovulatory granulosa cells involves mitogen-activated protein kinase activation and modulation of DAX-1 and steroidogenic factor-1,” *Journal of Clinical Endocrinology and Metabolism*, vol. 88, no. 5, pp. 2288–2299, 2003.

[53] A. C. Newton, “Protein kinase C: poised to signal,” *American Journal of Physiology*, vol. 298, no. 3, pp. E395–E402, 2010.

[54] P. R. Manna, M. T. Dyson, Y. Jo, and D. M. Stocco, “Role of dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the x chromosome, gene 1 in protein kinase a- and protein kinase c-mediated regulation of the steroidogenic acute regulatory protein expression in mouse Leydig tumor cells: mechanism of action,” *Endocrinology*, vol. 150, no. 1, pp. 187–199, 2009.